X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3020) 3020
Magazine Article (14) 14
Book Chapter (4) 4
Book Review (2) 2
Conference Proceeding (1) 1
Publication (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2388) 2388
valine - analogs & derivatives (2175) 2175
valine - therapeutic use (1838) 1838
male (1502) 1502
female (1355) 1355
valsartan (1156) 1156
tetrazoles - therapeutic use (956) 956
middle aged (932) 932
acyclovir - analogs & derivatives (792) 792
adult (717) 717
acyclovir - therapeutic use (715) 715
antiviral agents - therapeutic use (702) 702
aged (673) 673
animals (644) 644
hypertension - drug therapy (573) 573
antihypertensive agents - therapeutic use (566) 566
treatment outcome (492) 492
valine - administration & dosage (459) 459
pharmacology & pharmacy (455) 455
valine - pharmacology (441) 441
angiotensin ii type 1 receptor blockers - therapeutic use (398) 398
valine (392) 392
drug therapy, combination (381) 381
hypertension (360) 360
blood pressure - drug effects (329) 329
valine - adverse effects (326) 326
rats (313) 313
double-blind method (310) 310
valacyclovir (280) 280
tetrazoles - pharmacology (275) 275
peripheral vascular disease (242) 242
tetrazoles - administration & dosage (234) 234
angiotensin-converting enzyme inhibitors - therapeutic use (218) 218
hypertension - physiopathology (207) 207
mice (206) 206
acyclovir (201) 201
time factors (197) 197
cardiac & cardiovascular systems (196) 196
medicine, general & internal (196) 196
valine - genetics (192) 192
adolescent (191) 191
tetrazoles - adverse effects (190) 190
drug therapy (188) 188
risk factors (180) 180
research (176) 176
double-blind (174) 174
dose-response relationship, drug (173) 173
acyclovir - administration & dosage (172) 172
analysis (170) 170
prospective studies (170) 170
amino acids (164) 164
therapy (164) 164
antihypertensive agents - administration & dosage (162) 162
aged, 80 and over (161) 161
angiotensin receptor antagonists (161) 161
antiviral agents - administration & dosage (160) 160
heart failure - drug therapy (159) 159
care and treatment (151) 151
administration, oral (148) 148
amlodipine - therapeutic use (148) 148
disease (148) 148
health aspects (148) 148
mortality (148) 148
neurosciences (144) 144
blood pressure (141) 141
blood-pressure (139) 139
follow-up studies (139) 139
prevention (137) 137
randomized controlled trials as topic (135) 135
antihypertensive agents - pharmacology (134) 134
infectious diseases (134) 134
leucine (134) 134
2-aminopurine - analogs & derivatives (132) 132
angiotensin (132) 132
antihypertensive agents - adverse effects (132) 132
herpes zoster - drug therapy (129) 129
oncology (128) 128
internal medicine (124) 124
2-aminopurine - therapeutic use (123) 123
angiotensin ii type 1 receptor blockers - pharmacology (122) 122
herpes genitalis - drug therapy (121) 121
metabolism (121) 121
mutation (121) 121
risk (121) 121
heart failure (120) 120
valine - pharmacokinetics (120) 120
abridged index medicus (118) 118
acyclovir - adverse effects (117) 117
young adult (117) 117
expression (114) 114
hypertension - complications (114) 114
isoleucine (114) 114
medicine (114) 114
methionine - genetics (114) 114
proteins (114) 114
amlodipine (111) 111
immunology (111) 111
medicine & public health (111) 111
valine - chemistry (111) 111
antiviral agents - adverse effects (108) 108
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2823) 2823
German (70) 70
French (52) 52
Chinese (36) 36
Japanese (35) 35
Russian (29) 29
Spanish (20) 20
Italian (6) 6
Hungarian (5) 5
Dutch (3) 3
Polish (3) 3
Finnish (2) 2
Swedish (2) 2
Danish (1) 1
Romanian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Psychiatry and clinical neurosciences, ISSN 1323-1316, 2015, Volume 69, Issue 6, pp. 321 - 334
Tardive dyskinesia is a serious, disabling and potentially permanent, neurological hyperkinetic movement disorder that occurs after months or years of taking... 
first‐generation agents | schizophrenia | management | second‐generation agents | tardive dyskinesia | second-generation agents | first-generation agents | VITAMIN-E TREATMENT | NEUROTROPHIC FACTOR LEVELS | SCHIZOPHRENIC-PATIENTS | PSYCHIATRY | GINKGO-BILOBA | CHAIN AMINO-ACIDS | NEUROSCIENCES | ATYPICAL ANTIPSYCHOTICS | CLINICAL NEUROLOGY | HYPERKINETIC MOVEMENT-DISORDERS | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | ESSENTIAL FATTY-ACIDS | Stilbenes - therapeutic use | Antipsychotic Agents - adverse effects | Humans | Propranolol - therapeutic use | Leucine - therapeutic use | Dopamine Agents - therapeutic use | Amantadine - therapeutic use | Piracetam - therapeutic use | Pyridoxine - therapeutic use | Clonazepam - therapeutic use | Drugs, Chinese Herbal - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Adrenergic Uptake Inhibitors - therapeutic use | Anticonvulsants - therapeutic use | Nootropic Agents - therapeutic use | Isoleucine - therapeutic use | Vitamins - therapeutic use | Ginkgo biloba | alpha-Tocopherol - therapeutic use | Antioxidants - therapeutic use | Movement Disorders - etiology | Piracetam - analogs & derivatives | Melatonin - therapeutic use | Fatty Acids, Omega-3 - therapeutic use | Valine - therapeutic use | Isoxazoles - therapeutic use | Plant Extracts - therapeutic use | Movement Disorders - drug therapy | Tetrabenazine - therapeutic use | Schizophrenia | Movement disorders | Tardive dyskinesia | Medical research
Journal Article
Mayo Clinic Proceedings, ISSN 0025-6196, 2011, Volume 86, Issue 10, pp. 1009 - 1026
.... This review article is structured to discuss antiviral therapeutics on the basis of these 3 major antiviral categories, with the caveat that some drugs discussed... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | HERPES-SIMPLEX-VIRUS | TENOFOVIR DISOPROXIL FUMARATE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | POSITIVE CHRONIC HEPATITIS | CHRONIC HEPATITIS-B | ALPHA-2A PLUS RIBAVIRIN | CONGO HEMORRHAGIC-FEVER | ACUTE INTERSTITIAL NEPHRITIS | RECURRENT GENITAL HERPES | HIV-INFECTED PATIENTS | Acyclovir - therapeutic use | Foscarnet - pharmacology | Hepatitis C - drug therapy | HIV Infections - epidemiology | Humans | Ganciclovir - analogs & derivatives | Interferons - therapeutic use | Oligopeptides - therapeutic use | Hepatitis - drug therapy | Valacyclovir | Adenine - therapeutic use | Lamivudine - therapeutic use | Ganciclovir - therapeutic use | Proline - pharmacology | Protease Inhibitors - therapeutic use | Guanine - therapeutic use | Oseltamivir - pharmacology | Virus Replication - drug effects | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Valganciclovir | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Comorbidity | Interferons - pharmacology | Pyrimidinones - therapeutic use | Acyclovir - pharmacology | Zanamivir - therapeutic use | Herpesviridae Infections - drug therapy | Thymidine - analogs & derivatives | Valine - therapeutic use | Oligopeptides - pharmacology | Telbivudine | Ribavirin - pharmacology | Guanine - analogs & derivatives | Oseltamivir - therapeutic use | Guanine - pharmacology | Hepatitis C - epidemiology | Nucleosides - pharmacology | Ganciclovir - pharmacology | Pyrimidinones - pharmacology | Influenza, Human - drug therapy | Drug Therapy, Combination | Nucleosides - therapeutic use | Acyclovir - analogs & derivatives | Ribavirin - therapeutic use | Valine - analogs & derivatives | Zanamivir - pharmacology | Adenine - pharmacology | Proline - therapeutic use | Organophosphonates - pharmacology | Hepatitis B, Chronic - drug therapy | HIV Infections - drug therapy | Lamivudine - pharmacology | Foscarnet - therapeutic use | Valine - pharmacology | Amantadine - pharmacology | Antiviral agents | Diagnosis | Research | Drug therapy | HIV infection | Health aspects | Symposium on Antimicrobial Therapy
Journal Article
Journal Article
Pediatric rheumatology online journal, ISSN 1546-0096, 2016, Volume 14, Issue 1, p. 34
Journal Article
PloS one, ISSN 1932-6203, 2012, Volume 7, Issue 3, p. e33559
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2010, Volume 362, Issue 16, pp. 1477 - 1490
In this large clinical trial, the angiotensin-receptor blocker valsartan reduced the risk of diabetes in patients with impaired glucose tolerance. However, the... 
FASTING GLUCOSE | TRIAL | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | LIFE-STYLE INTERVENTIONS | DISEASE | PREVENTION | COMPONENTS | IMPAIRED GLUCOSE-TOLERANCE | MELLITUS | CONVERTING-ENZYME-INHIBITORS | Angiotensin II Type 1 Receptor Blockers - adverse effects | Follow-Up Studies | Phenylalanine - analogs & derivatives | Valsartan | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Body Weight - drug effects | Male | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Cyclohexanes - therapeutic use | Glucose Intolerance - drug therapy | Exercise | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Phenylalanine - therapeutic use | Drug Therapy, Combination | Hypoglycemic Agents - therapeutic use | Blood Glucose - analysis | Double-Blind Method | Risk Factors | Valine - analogs & derivatives | Diabetes Mellitus, Type 2 - prevention & control | Proportional Hazards Models | Blood Glucose - drug effects | Glucose Intolerance - diet therapy | Tetrazoles - therapeutic use | Valine - therapeutic use | Tetrazoles - adverse effects | Valine - adverse effects | Glucose Intolerance - therapy | Evaluation | Care and treatment | Glucose intolerance | Diabetes | Cardiovascular diseases | Drug therapy | Cardiovascular disease
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2010, Volume 362, Issue 16, pp. 1463 - 1476
Among patients with impaired glucose tolerance, the short-acting insulin secretagogue nateglinide did not reduce the incidence of diabetes over the course of 5... 
TRIAL | MEDICINE, GENERAL & INTERNAL | LIFE-STYLE | DIET | INSULIN-SECRETION | DISEASE | PREVENTION | IMPAIRED GLUCOSE-TOLERANCE | ACARBOSE | MELLITUS | NIDDM | Follow-Up Studies | Phenylalanine - adverse effects | Phenylalanine - analogs & derivatives | Valsartan | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Body Weight - drug effects | Male | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Cyclohexanes - therapeutic use | Glucose Intolerance - drug therapy | Exercise | Treatment Failure | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Cyclohexanes - adverse effects | Phenylalanine - therapeutic use | Drug Therapy, Combination | Hypoglycemic Agents - therapeutic use | Blood Glucose - analysis | Double-Blind Method | Risk Factors | Valine - analogs & derivatives | Diabetes Mellitus, Type 2 - prevention & control | Kaplan-Meier Estimate | Proportional Hazards Models | Blood Glucose - drug effects | Glucose Intolerance - diet therapy | Tetrazoles - therapeutic use | Valine - therapeutic use | Hypoglycemic Agents - adverse effects | Glucose Intolerance - therapy | Evaluation | Care and treatment | Glucose intolerance | Diabetes | Cardiovascular diseases | Drug therapy | Nateglinide | Studies | Cardiovascular disease
Journal Article
Hypertension: Journal of the American Heart Association, ISSN 0194-911X, 08/2002, Volume 40, Issue 2, pp. 117 - 123
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2007, Volume 370, Issue 9583, pp. 221 - 229
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 380, Issue 9851, pp. 1387 - 1395